17-Acetamido-4-azasteroid derivatives as androgen receptor modulators
View Patent ↗Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive impairment, decreased libido, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
1. A compound of structural formula I:
or a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein:
X is a halogen;
A is C 0-12 alkyl;
R 1 is C 1-3 alkyl optionally substituted with one to seven fluorine atoms;
R 2 and R 3 are each independently chosen from:
hydrogen,
halogen,
C 1-8 alkyl,
amino C 0-6 alkyl,
C 1-6 alkylamino C 0-6 alkyl,
(C 1-6 alkyl) 2 amino C 0-6 alkyl,
C 1-6 alkoxy C 0-6 alkyl,
hydroxycarbonyl C 0-6 alkyl,
C 1-6 alkoxycarbonyl C 0-6 alkyl,
hydroxycarbonyl C 1-6 alkyloxy,
hydroxy C 0-6 -alkyl,
cyano,
perfluoroC 1-4 alkyl,
perfluoroC 1-4 alkoxy,
C 0-6 alkylcarbonyl,
C 1-6 alkylcarbonyloxy,
C 1-6 alkylcarbonylamino,
C 1-6 alkylsulfonylamino,
C 1-6 alkoxycarbonylamino,
C 1-6 alkylaminocarbonylamino,
(C 1-6 alkyl) 2 aminocarbonylamino, and
(C 1-6 alkyl) 2 aminocarbonyloxy,
and wherein
R 2 and R 3 together with the carbon atom to which they are attached can optionally form a spiro-C 3-6 cycloalkyl group, or an oxo group, and
R 2 and R 3 are each independently optionally substituted with at least one R 8 ;
R 4 , R 5 , R 6 , and R 7 are each independently chosen from:
hydrogen,
halogen,
(carbonyl) 0-1 C 1-10 alkyl,
(carbonyl) 0-1 C 2-10 alkenyl,
(carbonyl) 0-1 C 2-10 alkynyl,
C 3-8 cycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 3-8 heterocycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 1-4 acylamino C 0-10 alkyl,
C 0-10 alkylamino C 0-10 alkyl,
C 0-10 alkylamino C 0-10 alkylaminocarbonyl,
di-(C 1-10 alkyl)amino C 0-10 alkyl,
arylC 0-10 alkylamino C 0-10 alkyl,
(arylC 0-10 alkyl) 2 amino C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkylamino C 0-10 alkyl,
C 3-8 heterocyclyl C 0-10 alkylamino C 0-10 alkyl,
(C 3-8 cycloalkyl C 0-10 alkyl) 2 amino C 0-10 alkyl,
(C 3-8 heterocyclyl C 0-10 alkyl) 2 amino C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkyl aminocarbonylamino,
(C 1-10 alkyl) 2 aminocarbonylamino,
(aryl C 1-10 alkyl) 1-2 aminocarbonylamino,
C 0-10 alkyl aminocarbonylamino,
C 3-8 heterocyclyl C 0-10 alkyl aminocarbonylamino,
(C 1-10 alkyl) 2 aminocarbonyl C 0-10 alkyl,
(aryl C 1-10 alkyl) 1-2 aminocarbonyl C 0-10 alkyl,
C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
C 3-8 heterocyclyl C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
aryl C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
(C 1-10 alkyl) 2 aminocarbonyl,
(aryl C 1-10 alkyl) 1-2 aminocarbonyl,
C 1-10 alkoxy (carbonyl) 0-1 C 0-10 alkyl,
C 0-10 alkyl carbonylamino(C 0-10 alkyl),
C 0-10 alkoxy carbonylamino(C 0-10 alkyl),
carboxy C 0-10 alkylamino,
carboxy C 0-10 alkyl,
carboxy C 3-8 cycloalkyl,
C 1-10 alkoxy,
C 1-10 alkyloxy C 0-10 alkyl,
C 1-10 alkylcarbonyloxy,
C 3-8 heterocyclyl C 0-10 alkylcarbonyloxy,
C 3-8 cycloalkyl C 0-10 alkylcarbonyloxy,
aryl C 0-10 alkylcarbonyloxy,
C 1-10 alkylcarbonyloxy amino,
C 3-8 heterocyclyl C 0-10 alkylcarbonyloxy amino,
C 3-8 cycloalkyl C 0-10 alkylcarbonyloxy amino,
aryl C 0-10 alkylcarbonyloxy amino,
(C 1-10 alkyl) 2 aminocarbonyloxy,
(aryl C 0-10 alkyl) 1-2 aminocarbonyloxy,
(C 3-8 heterocyclyl C 0-10 alkyl) 1-2 aminocarbonyloxy,
(C 3-8 cycloalkyl C 0-10 alkyl) 1-2 aminocarbonyloxy,
hydroxy C 0-10 alkyl,
hydroxycarbonylC 0-10 alkoxy,
hydroxycarbonylC 0-10 alkyloxy,
C 1-10 alkylthio,
C 1-10 alkylsulfinyl,
aryl C 0-10 alkylsulfinyl,
C 3-8 heterocyclyl C 0-10 alkylsulfinyl,
C 3-8 cycloalkyl C 0-10 alkylsulfinyl,
C 1-10 alkylsulfonyl,
aryl C 0-10 alkylsulfonyl,
C 3-8 heterocyclyl C 0-10 alkylsulfonyl,
C 3-8 cycloalkyl C 0-10 alkylsulfonyl,
C 1-10 alkylsulfonylamino,
aryl C 1-10 alkylsulfonylamino,
C 3-8 heterocyclyl C 1-10 alkylsulfonylamino,
C 3-8 cycloalkyl C 1-10 alkylsulfonylamino,
cyano,
nitro,
perfluoroC 1-6 alkyl, and
perfluoroC 1-6 alkoxy;
wherein R 4 and R 5 can be taken together with the carbon to which they are attached, to form a monocyclic nonaromatic ring system with 5-7 members and having in ring, 0, 1, 2, 3, or 4 heteroatoms selected from the group consisting of N, O, and S, and
R 4 , R 5 , R 6 , and R 7 are each independently optionally substituted with at least one R 8 ; and
R 8 is chosen from:
hydrogen,
halogen,
(carbonyl) 0-1 C 1-10 alkyl,
(carbonyl) 0-1 C 2-10 alkenyl,
(carbonyl) 0-1 C 2-10 alkynyl,
(carbonyl) 0-1 aryl C 1-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 3-8 heterocycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 1-4 acylamino C 0-10 alkyl,
C 0-10 alkylamino C 0-10 alkyl,
C 0-10 alkylamino C 0-10 alkylaminocarbonyl,
di-(C 1-10 alkyl)amino C 0-10 alkyl,
arylC 0-10 alkylamino C 0-10 alkyl,
(arylC 0-10 alkyl) 2 amino C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkylamino C 0-10 alkyl,
C 3-8 heterocyclyl C 0-10 alkylamino C 0-10 alkyl,
(C 3-8 cycloalkyl C 0-10 alkyl) 2 amino C 0-10 alkyl,
(C 3-8 heterocyclyl C 0-10 alkyl) 2 amino C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkyl aminocarbonylamino,
(C 1-10 alkyl) 2 aminocarbonylamino,
(aryl C 1-10 alkyl) 1-2 aminocarbonylamino,
C 0-10 alkyl aminocarbonylamino,
C 3-8 heterocyclyl C 0-10 alkyl aminocarbonylamino,
(C 1-10 alkyl) 2 aminocarbonyl C 0-10 alkyl,
(aryl C 1-10 alkyl) 1-2 aminocarbonyl C 0-10 alkyl,
C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
C 3-8 heterocyclyl C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
aryl C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
(C 1-10 alkyl) 2 aminocarbonyl,
(aryl C 1-10 alkyl) 1-2 aminocarbonyl,
C 1-10 alkoxy (carbonyl) 0-1 C 0-10 alkyl,
C 0-10 alkyl carbonylamino(C 0-10 alkyl),
C 0-10 alkoxy carbonylamino(C 0-10 alkyl),
carboxy C 0-10 alkylamino,
carboxy C 0-10 alkyl,
carboxy C 3-8 cycloalkyl,
C 1-10 alkoxy,
C 1-10 alkyloxy C 0-10 alkyl,
C 1-10 alkylcarbonyloxy,
C 3-8 heterocyclyl C 0-10 alkylcarbonyloxy,
C 3-8 cycloalkyl C 0-10 alkylcarbonyloxy,
aryl C 0-10 alkylcarbonyloxy,
C 1-10 alkylcarbonyloxy amino,
C 3-8 heterocyclyl C 0-10 alkylcarbonyloxy amino,
C 3-8 cycloalkyl C 0-10 alkylcarbonyloxy amino,
aryl C 0-10 alkylcarbonyloxy amino,
(C 1-10 alkyl) 2 aminocarbonyloxy,
(aryl C 0-10 alkyl) 1-2 aminocarbonyloxy,
(C 3-8 heterocyclyl C 0-10 alkyl) 1-2 aminocarbonyloxy,
(C 3-8 cycloalkyl C 0-10 alkyl) 1-2 aminocarbonyloxy,
hydroxy C 0-10 alkyl,
hydroxycarbonylC 0-10 alkoxy,
hydroxycarbonylC 0-10 alkyloxy,
C 1-10 alkylthio,
C 1-10 alkylsulfinyl,
aryl C 0-10 alkylsulfinyl,
C 3-8 heterocyclyl C 0-10 alkylsulfinyl,
C 3-8 cycloalkyl C 0-10 alkylsulfinyl,
C 1-10 alkylsulfonyl,
aryl C 0-10 alkylsulfonyl,
C 3-8 heterocyclyl C 0-10 alkylsulfonyl,
C 3-8 cycloalkyl C 0-10 alkylsulfonyl,
C 1-10 alkylsulfonylamino,
aryl C 1-10 alkylsulfonylamino,
C 3-8 heterocyclyl C 1-10 alkylsulfonylamino,
C 3-8 cycloalkyl C 1-10 alkylsulfonylamino,
cyano,
nitro,
perfluoroC 1-6 alkyl, and
perfluoroC 1-6 alkoxy;
wherein, R 8 is optionally substituted with one or more groups selected from hydrogen, OH, (C 1-6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1 -C 6 alkyl, NO 2 , trifluoromethoxy, trifluoroethoxy, —O b (C 1-10 )perfluoroalkyl, and NH 2 .
2. A compound of structural formula II:
a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein:
X is halogen;
A is C 1-3 alkyl;
R 2 and R 3 are each independently chosen from:
hydrogen,
halogen,
C 1-8 alkyl,
amino C 0-6 alkyl,
C 1-6 alkylamino C 0-6 alkyl,
(C 1-6 alkyl) 2 amino C 0-6 alkyl,
C 1-6 alkoxy C 0-6 alkyl,
hydroxycarbonyl C 0-6 alkyl,
C 1-6 alkoxycarbonyl C 0-6 alkyl,
hydroxycarbonyl C 1-6 alkyloxy,
hydroxy C 0-6 alkyl,
cyano,
perfluoroC 1-4 alkyl,
perfluoroC 1-4 alkoxy,
C 0-6 alkylcarbonyl,
C 1-6 alkylcarbonyloxy,
C 1-6 alkylcarbonylamino,
C 1-6 alkylsulfonylamino,
C 1-6 alkoxycarbonylamino,
C 1-6 alkylaminocarbonylamino,
(C 1-6 alkyl) 2 aminocarbonylamino, and
(C 1-6 alkyl) 2 aminocarbonyloxy,
and wherein
R 2 and R 3 together with the carbon atom to which they are attached can optionally form a spiro-C 3-6 cycloalkyl group, or an oxo group, and
R 2 and R 3 are each independently optionally substituted with at least one R 8 ;
R 4 , R 5 , and R 6 are each independently chosen from:
hydrogen,
halogen,
(carbonyl) 0-1 C 1-10 alkyl,
(carbonyl) 0-1 C 2-10 alkenyl,
(carbonyl) 0-1 C 2-10 alkynyl,
C 3-8 cycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 3-8 heterocycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 1-4 acylamino C 0-10 alkyl,
C 0-10 alkylamino C 0-10 alkyl,
C 0-10 alkylamino C 0-10 alkylaminocarbonyl,
di-(C 1-10 alkyl)amino C 0-10 alkyl,
arylC 0-10 alkylamino C 0-10 alkyl,
(arylC 0-10 alkyl) 2 amino C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkylamino C 0-10 alkyl,
C 3-8 heterocyclyl C 0-10 alkylamino C 0-10 alkyl,
(C 3-8 cycloalkyl C 0-10 alkyl) 2 amino C 0-10 alkyl,
(C 3-8 heterocyclyl C 0-10 alkyl) 2 amino C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkyl aminocarbonylamino,
(C 1-10 alkyl) 2 aminocarbonylamino,
(aryl C 1-10 alkyl) 1-2 aminocarbonylamino,
C 0-10 alkyl aminocarbonylamino,
C 3-8 heterocyclyl C 0-10 alkyl aminocarbonylamino,
(C 1-10 alkyl) 2 aminocarbonyl C 0-10 alkyl,
(aryl C 1-10 alkyl) 1-2 aminocarbonyl C 0-10 alkyl,
C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
C 3-8 heterocyclyl C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
aryl C 0-10 alkyl aminocarbonyl C 0-10 alkyl,
(C 1-10 alkyl) 2 aminocarbonyl,
(aryl C 1-10 alkyl) 1-2 aminocarbonyl,
C 1-10 alkoxy (carbonyl) 0-1 C 0-10 alkyl,
C 0-10 alkyl carbonylamino(C 0-10 alkyl),
C 0-10 alkoxy carbonylamino(C 0-10 alkyl),
carboxy C 0-10 alkylamino,
carboxy C 0-10 alkyl,
carboxy C 3-8 cycloalkyl,
C 1-10 alkoxy,
C 1-10 alkyloxy C 0-10 alkyl,
C 1-10 alkylcarbonyloxy,
C 3-8 heterocyclyl C 0-10 alkylcarbonyloxy,
C 3-8 cycloalkyl C 0-10 alkylcarbonyloxy,
aryl C 0-10 alkylcarbonyloxy,
C 1-10 alkylcarbonyloxy amino,
C 3-8 heterocyclyl C 0-10 alkylcarbonyloxy amino,
C 3-8 cycloalkyl C 0-10 alkylcarbonyloxy amino,
aryl C 0-10 alkylcarbonyloxy amino,
(C 1-10 alkyl) 2 aminocarbonyloxy,
(aryl C 0-10 alkyl) 1-2 aminocarbonyloxy,
(C 3-8 heterocyclyl C 0-10 alkyl) 1-2 aminocarbonyloxy,
(C 3-8 cycloalkyl C 0-10 alkyl) 1-2 aminocarbonyloxy,
hydroxy C 0-10 alkyl,
hydroxycarbonylC 0-10 alkoxy,
hydroxycarbonylC 0-10 alkyloxy,
C 1-10 alkylthio,
C 1-10 alkylsulfinyl,
aryl C 0-10 alkylsulfinyl,
C 3-8 heterocyclyl C 0-10 alkylsulfinyl,
C 3-8 cycloalkyl C 0-10 alkylsulfinyl,
C 1-10 alkylsulfonyl,
aryl C 0-10 alkylsulfonyl,
C 3-8 heterocyclyl C 0-10 alkylsulfonyl,
C 3-8 cycloalkyl C 0-10 alkylsulfonyl,
C 1-10 alkylsulfonylamino,
aryl C 1-10 alkylsulfonylamino,
C 3-8 heterocyclyl C 1-10 alkylsulfonylamino,
C 3-8 cycloalkyl C 1-10 alkylsulfonylamino,
cyano,
nitro,
perfluoroC 1-6 alkyl, and
perfluoroC 1-6 alkoxy;
wherein R 4 and R 5 can be taken together with the carbon to which they are attached, to form a monocyclic nonaromatic ring system with 5-7 members and having in ring, 0, 1, 2, 3, or 4 heteroatoms selected from the group consisting of N, O, and S, and
and R 4 , R 5 , and R 6 are each independently optionally substituted with at least one R 8 ;
R 7 is chosen from hydrogen, halogen, C 1-10 alkyl, optionally substituted with at least one R 8 ;
R 8 is chosen from:
hydrogen,
halogen,
(carbonyl) 0-1 C 1-10 alkyl,
(carbonyl) 0-1 C 2-10 alkenyl,
(carbonyl) 0-1 C 2-10 alkynyl,
C 3-8 cycloalkyl C 0-10 alkyl,
C 3-8 heterocycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 1-4 acylamino C 0-10 alkyl,
C 0-10 alkylamino C 0-10 alkyl,
di-(C 1-10 alkyl)amino C 0-10 alkyl,
arylC 0-10 alkylamino C 0-10 alkyl,
(arylC 1-10 alkyl) 2 amino C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkylamino C 0-10 alkyl,
C 3-8 heterocyclyl C 0-10 alkylamino C 0-10 alkyl,
(C 1-10 alkyl) 2 aminocarbonyl,
C 1-10 alkoxy (carbonyl) 0-1 C 0-10 alkyl,
C 1-10 alkyloxy C 0-10 alkyl,
(C 1-10 alkyl) 2 aminocarbonyloxy,
hydroxycarbonylC 0-10 alkoxy,
(C 1-10 alkyl) 2 aminocarbonyloxy,
(aryl C 0-10 alkyl) 1-2 aminocarbonyloxy,
hydroxy C 0-10 alkyl,
C 1-10 alkylsulfonyl,
C 1-10 alkylsulfonylamino,
aryl C 1-10 alkylsulfonylamino,
C 3-8 heterocyclyl C 1-10 alkylsulfonylamino,
C 3-8 cycloalkyl C 1-10 alkylsulfonylamino,
cyano,
nitro,
perfluoroC 1-6 alkyl, and
perfluoroC 1-6 alkoxy; and
wherein, R 8 is optionally substituted with one or more groups selected from hydrogen, OH, (C 1-6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1-6 alkyl, NO 2 , trifluoromethoxy, trifluoroethoxy, —O b (C 1-10 )perfluoroalkyl, and NH 2 ;
provided that when R 4 and R 5 are taken together with the carbon to which they are attached, to form a monocyclic or bicyclic ring system then A is chosen from C 2-3 alkyl.
3. A compound according to claim 2 of structural formula III:
a pharmaceutically acceptable salt or a stereoisomer thereof,
wherein:
X is halogen;
A is C 1-4 alkyl;
optionally substituted with at least one group chosen from OH, (C 1-6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1 -C 6 alkyl, NO 2 , trifluoromethoxy, trifluoroethoxy, —O b (C 1-10 )perfluoroalkyl, and NH 2 ;
is chosen from is chosen from cyclopropyl, cyclohexyl, cyclohexadienyl, cyclopentadienyl, dioxidotetrahydrothienyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolidinyl, pyrrolinyl, oxazinyl, tetrahydrofuranyl, and tetrahydro-2H-pyranyl,
wherein
is optionally substituted with one or more R 9 ;
R 2 and R 3 are each independently chosen from:
hydrogen,
halogen,
C 1-8 alkyl,
amino C 0-6 alkyl,
C 1-6 alkylamino C 0-6 alkyl,
(C 1-6 alkyl) 2 amino C 0-6 alkyl,
C 1-6 alkoxy C 0-6 alkyl,
hydroxycarbonyl C 0-6 alkyl,
C 1-6 alkoxycarbonyl C 0-6 alkyl,
hydroxycarbonyl C 1-6 alkyloxy,
hydroxy C 0-6 alkyl,
cyano,
perfluoroC 1-4 alkyl,
perfluoroC 1-4 alkoxy,
C 0-6 alkylcarbonyl,
C 1-6 alkylcarbonyloxy,
C 1-6 alkylcarbonylamino,
C 1-6 alkylsulfonylamino,
C 1-6 alkoxycarbonylamino,
C 1-6 alkylaminocarbonylamino,
(C 1-6 alkyl) 2 aminocarbonylamino, and
(C 1-6 alkyl) 2 aminocarbonyloxy,
and wherein
R 2 and R 3 together with the carbon atom to which they are attached can optionally form a spiro-C 3-6 cycloalkyl group, or an oxo group, and
R 2 and R 3 are each independently optionally substituted with at least one R 8 ;
R 7 and R 9 are each independently chosen from:
hydrogen,
(carbonyl) 0-1 C 1-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 3-8 heterocycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 0-10 alkylamino C 0-10 alkyl,
carboxy C 0-10 alkyl,
carboxy C 3-8 cycloalkyl,
C 1-10 alkyloxy C 0-10 alkyl,
hydroxy C 0-10 alkyl, and
perfluoroC 1-6 alkyl, and
wherein and R 7 and R 9 are each independently optionally substituted with at least one R 8 ; and
R 8 is chosen from:
hydrogen,
halogen,
(carbonyl) 0-1 C 1-10 alkyl,
(carbonyl) 0-1 C 2-10 alkenyl,
C 3-8 cycloalkyl C 0-10 alkyl,
C 3-8 heterocycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 1-4 acylamino C 0-10 alkyl,
C 0-10 alkylamino C 0-10 alkyl,
di-(C 1-10 alkyl)amino C 0-10 alkyl,
arylC 0-10 alkylamino C 0-10 alkyl,
(arylC 0-10 alkyl) 2 amino C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkylamino C 0-10 alkyl,
C 3-8 heterocyclyl C 0-10 alkylamino C 0-10 alkyl,
(C 1-10 alkyl) 2 aminocarbonyl,
C 1-10 alkoxy (carbonyl) 0-1 C 0-10 alkyl,
C 1-10 alkyloxy C 0-10 alkyl,
(C 1-10 alkyl) 2 aminocarbonyloxy,
hydroxycarbonylC 0-10 alkoxy,
(C 1-10 alkyl) 2 aminocarbonyloxy,
hydroxy C 0-10 alkyl,
C 1-10 alkylsulfonyl,
C 1-10 alkylsulfonylamino,
aryl C 1-10 alkylsulfonylamino,
C 3-8 heterocyclyl C 1-10 alkylsulfonylamino,
C 3-8 cycloalkyl C 1-10 alkylsulfonylamino,
cyano,
nitro,
perfluoroC 1-6 alkyl, and
perfluoroC 1-6 alkoxy,
wherein, R 8 is optionally substituted with one or more groups selected from hydrogen, OH, (C 1-6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1 -C 6 alkyl, NO 2 , trifluoromethoxy, trifluoroethoxy, —O b (C 1-10 )perfluoroalkyl, and NH 2 .
4. A compound according to claim 3 ,
wherein
is chosen from dioxidotetrahydrothienyl, morpholinyl, piperidinyl, tetrahydrofuranyl, and tetrahydro-2H-pyranyl,
wherein
is optionally substituted with one or more R 9 ,
R 9 is chosen from:
hydrogen,
(carbonyl) 0-1 C 1-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkyl(carbonyl) 0-1 ,
C 0-10 alkylamino C 0-10 alkyl,
carboxy C 0-10 alkyl,
carboxy C 3-8 cycloalkyl,
C 1-10 alkyloxy C 0-10 alkyl,
hydroxy C 0-10 alkyl, and
perfluoroC 1-6 alkyl, and
wherein R 9 is optionally substituted with at least one R 8 ; and
R 8 is chosen from:
hydrogen,
halogen,
(carbonyl) 0-1 C 1-10 alkyl,
(carbonyl) 0-1 C 2-10 alkenyl,
C 3-8 cycloalkyl C 0-10 alkyl,
C 1-4 acylamino C 0-10 alkyl,
C 0-10 alkylamino C 0-10 alkyl,
di-(C 1-10 alkyl)amino C 0-10 alkyl,
arylC 0-10 alkylamino C 0-10 alkyl,
(arylC 0-10 alkyl) 2 amino C 0-10 alkyl,
C 3-8 cycloalkyl C 0-10 alkylamino C 0-10 alkyl,
C 3-8 heterocyclyl C 0-10 alkylamino C 0-10 alkyl,
(C 1-10 alkyl) 2 aminocarbonyl,
C 1-10 alkoxy (carbonyl) 0-1 C 0-10 alkyl,
C 1-10 alkyloxy C 0-10 alkyl,
(C 1-10 alkyl) 2 aminocarbonyloxy,
hydroxycarbonylC 0-10 alkoxy,
(C 1-10 alkyl) 2 aminocarbonyloxy,
hydroxy C 0-10 alkyl,
C 1-10 alkylsulfonyl,
C 1-0 alkylsulfonylamino,
aryl C 1-10 alkylsulfonylamino,
C 3-8 heterocyclyl C 1-10 alkylsulfonylamino,
C 3-8 cycloalkyl C 1-10 alkylsulfonylamino,
cyano,
nitro,
perfluoroC 1-6 alkyl, and
perfluoroC 1-6 alkoxy; and
wherein, and R 8 optionally substituted with one or more groups selected from hydrogen, OH, (C 1-6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1 -C 6 alkyl, NO 2 , trifluoromethoxy, trifluoroethoxy, —O b (C 1-10 )perfluoroalkyl, and NH 2 .
5. A compound according to claim 3 , wherein X is fluorine.
6. A compound selected from:
N-(2,2,2-trifluoroethyl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-(1,1-dioxidotetrahydrothien-3-yl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N,N 2 -[(N 1 ,N 1 -dimethylglycinamidyl]-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-(tetrahydrofuran-2-ylmethyl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-(tetrahydro-2H-pyran-4-ylmethyl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-[2-(dimethylamino)ethyl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-[(1-tert-butyl-carboxylyl)piperidin-4-yl)methyl]-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-(2-methoxyethyl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-[(1-tert-butyl-carboxylyl)piperidin-3-yl)methyl]-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
and pharmaceutically acceptable salts and stereoisomers thereof.
7. A compound according to claim 6 selected from:
N-(2,2,2-trifluoroethyl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N,N 2 -[(N 1 ,N 1 -dimethylglycinamidyl]-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-[2-(dimethylamino)ethyl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-(2-methoxyethyl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
and pharmaceutically acceptable salts and stereoisomers thereof.
8. A compound according to claim 6 , selected from:
N-(1,1-dioxidotetrahydrothien-3-yl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-(tetrahydrofuran-2-ylmethyl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-(tetrahydro-2H-pyran-4-ylmethyl)-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-[(1-tert-butyl-carboxylyl)piperidin-4-yl)methyl]-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
N-[(1-tert-butyl-carboxylyl)piperidin-3-yl)methyl]-4-methyl-3-oxo-4-aza-5α-androst-1-en-17β-acetamide;
and pharmaceutically acceptable salts and stereoisomers thereof.